ALS
In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue giving them an experimental drug.
Trace Neuroscience Launches With $101M Series A Funding
The company is developing an antisense oligonucleotide to restore UNC13A protein expression, which it says could treat up to 97 percent of ALS patients.
UniQure Doses First Patient in Phase I/II Trial of SOD1-ALS Gene Therapy
Investigators will evaluate the safety, tolerability, and exploratory signs of efficacy, including neurofilament light chain and SOD1 protein.
GenieUs Genomics Aims to Stratify ALS Patients Using Bioinformatics Platform, Long-Read Sequencing
Premium
The Australian firm seeks to validate its DiGAP platform in a clinical study by categorizing ALS patients according to their most affected biological pathways.
The Dutch company is developing a pipeline of vectorized antibodies to clear pathological protein aggregates from affected cells in neurodegenerative disorders.